LRRK2 and Parkinson disease: CMA efficiency decreases with aging, and mutations in PD risk genes such as LRRK2 can interfere with CMA by blocking the LAMP2A multimerization required for translocation (Ho et al., 2020; Kabuta et al., 2008; Orenstein et al., 2013; Xilouri et al., 2009), resulting in αS accumulation on the lysosomal membrane and accelerating αS oligomerization (Ho et al., 2020; Orenstein et al., 2013).